Rekdal is one of the founders of Lytix Biopharma and its portfolio including LTX-315 and LTX-401. He served as a CEO of Lytix Biopharma in the first years after the company was established and has, until now, served as CSO and Head of R&D.

Director of the board Espen Johnsen says: “The appointment of Øystein Rekdal as acting CEO will secure continuity for the company’s.  Øystein knows the history of the company as well as our technology and development plans very well. We are sure he will use all his experience from the company in the CEO position. We are very grateful that Øystein is willing to serve as CEO and are looking very much forward to collaborate with him.”